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Abstract
Background: Ovarian cancer is the most lethal gynaecological malignancy in the United Kingdom (UK). Studies
have found that many women with ovarian cancer have symptoms for several months before diagnosis. Using a
symptoms-based tool to diagnose ovarian cancer (OC) earlier is appealing, but may increase general practitioner
(GP) workload because the symptoms are typically vague and non-specific. This study aimed to provide estimates
of the GP workload associated with offering symptoms-based ovarian cancer screening.
Methods: A cross-sectional analysis of electronic records from four general practices in England, UK. We downloaded
anonymous data on women aged 45–74 who consulted over one week to estimate the proportion who would be
offered ‘screening’ according to the UK National Institute for Health and Care Excellence (NICE) guidelines and a
symptoms index (Index 2) over one year. We used previous consultations (censoring women with no prior symptom at
the date of their last recorded consultation) to estimate the proportion of women presenting with a new (not recorded
in previous 12 months) NICE symptom each year.
Results: Data were obtained from 19,558 women. The proportion presenting over one week varied between practices
(5%-14%), however, the proportion with an OC symptom was similar (17% overall). Over one year, an estimated 51.8%
(95% CI 44.0%-59.7%) would present with an OC symptom, 26.6% (95% CI 19.3%-35.1%) with a NICE symptom and
20.3% (95% CI 13.7%-28.5%) with an Index 2 symptom. Each year, an estimated 11.9% (95% CI 5.0%-18.3%) of women
would present with a new NICE symptom.
Conclusion: One in two women aged 45–74 present to primary care at least once a year with an OC symptom, 11.9%
with a new NICE symptom. This would be comparable to 2 to 8 yearly screening (depending on what symptoms
triggered testing).
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Background
Ovarian cancer is the most lethal gynaecological malig-
nancy in the UK causing around 4,200 deaths per year [1].
The majority of women are diagnosed with advanced stage
disease and the lack of an effective screening mechanism
means that diagnosis relies on symptomatic presentation.
Numerous retrospective studies [2-13] have shown that
women have symptoms for many months before ovarian
cancer diagnosis. This has led to interest in using symp-
toms to prompt investigations which could hopefully facili-
tate earlier stage diagnosis. This would be a form of
targeted ‘screening’ in which women presenting to pri-
mary care with symptoms suggestive of ovarian cancer
would be offered a blood test (e.g. CA125 or any future
biomarker) and/or pelvic ultrasound. The challenge is that
ovarian cancer is rare, and the symptoms are relatively
common with non-malignant conditions in postmeno-
pausal women (in whom >80% of ovarian cancers occur).
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In the UK, NICE (National Institute for Health and
Clinical Excellence) guidelines for ovarian cancer rec-
ommend CA125 testing for persistent symptoms of
abdominal distension, feeling full quickly/loss of appe-
tite, pelvic/abdominal pain and urinary frequency or
urgency [14]. Urgent investigation for ovarian cancer is
only recommended for women with suspected ascites
or a palpable mass. In 2012, primary care physicians
(GPs) in England were given increased access to non-
obstetric ultrasound with the express purpose of aiding
ovarian cancer diagnosis [15]. However, there are few
data on the prevalence of ovarian cancer-like symptoms in
women presenting to primary care or in the general popu-
lation. Also, because of the growing demands on primary
care, activities that could increase GP workload need care-
ful assessment.
Electronic patient records (EPR) enable large amounts
of data to be obtained with a simple download. The aim
of this study was to use electronic medical records to
provide an unbiased estimate of the GP workload asso-
ciated with offering symptoms-based ovarian cancer
screening.
Methods
GP practices
We identified potential GP surgeries in London, Newbury,
Wokingham and Bracknell via research contacts and col-
laborators. Of those willing to participate we only included
those with a list size of at least 5500, that had been
using EMIS (Egton Medical Information Systems one of
the main software suppliers to UK general practices) LV
(Limited Version) for at least one year, had at least one
female GP (in case women are less likely to report gynae-
cological symptoms to a male GP), and no unusual demo-
graphic composition. The threshold for list size was
based on the average of 5891 patients for England set by
the 2004 General Medical Services contract [16].
Study population
Only anonymised data were used in the study, therefore
ethics approval was not necessary. We used EMIS to
download data on permanently registered women aged
45–74 years who presented over one week. Women
whose records showed that they had a history of ovarian
cancer or were actively receiving treatment for a malig-
nancy (except for hormonal treatment only) were excluded.
Data collection
Downloads took place between November 2007 and
May 2008. We developed a search strategy in EMIS LV
which downloaded data on women aged 45–74 who
consulted over one week. Data included the woman’s age,
medical history and details of the most recent previous
consultation entries up to a maximum of 10. The week
examined preceded the date of download by one day to
allow time for after-hours and home visits to be entered.
We also collected the following details from each
practice:
 List size (including breakdown of age and sex)
 Total number of women aged 45–74 in the practice
 Number of GPs
 Full-time or part-time work status of each GP
 Total number of women registered with the practice
Data cleaning
Consultation data in EMIS include entries that are not
actual consultations such as incoming letters, administra-
tive notes and laboratory test results. For each consult-
ation entry we determined who was seen/encountered
(from the name of the person who made the entry; eg a
doctor or receptionist’s name), the consultation location
(from the consultation type field; eg “GP surgery”, “path
lab”). Consultation entries were then limited to those that
were with a GP or a nurse and in-person (GP surgery or
home visits) or over the telephone.
The same researcher (AWL) extracted symptoms from
the consultation free text and clinical codes. Extracted
symptoms were then coded as relevant or not relevant
to ovarian cancer according to a pre-defined list of
symptoms most commonly reported by women with
ovarian cancer [2-10]. Symptoms included pelvic or
abdominal pain or discomfort; abdominal bloating;
increased abdominal size/abdominal distension; abdominal
lump; indigestion; constipation; diarrhoea; nausea or vomit-
ing; other gastrointestinal symptoms (eg wind, change in
bowel habit); loss of appetite; weight loss, fatigue; urinary
frequency or urgency; postmenopausal bleeding; and vagi-
nal discharge. Vaginal discharge is not usually considered
to be a typical ovarian cancer symptom, but was included
because we found it to be independently associated with
ovarian cancer in a case–control study [12]. A systematic
coding frame (compiled with the input of two gynaecolo-
gists: Professor Usha Menon and Dr Aarti Sharma) was
used to ensure symptoms were classified consistently.
Details of co-morbidities (type and date diagnosed/
recorded) were obtained from the women’s medical
history summary data.
Analysis
We estimated the proportion of women who would be
offered targeted ‘screening’ in GP primary care over one
week under two different scenarios. The first used NICE
guidelines which recommend CA125 testing in women
who have any one of persistent abdominal distension,
feeling full (early satiety) and/or loss of appetite, pelvic
or abdominal pain or increased urinary urgency and/or
frequency, on a persistent or frequent basis particularly
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more than 12 times per month [14]. We applied these
criteria to our data except for symptom frequency as this
information was not available in the GP notes. The sec-
ond used a symptoms index (Index 2) that we developed
in a previous study [12]. Women are considered positive
on Index 2 if they have any one of pelvic abdominal pain
or discomfort; loss of appetite; increase in abdominal size;
able to feel a lump in the abdomen; or vaginal discharge.
We also considered women who had two or more Index 2
symptoms given that the positive predictive value of
individual symptoms is low [17].
Targeted ovarian cancer ‘screening’ is unlikely to be
triggered by longstanding symptoms (unless there is
worsening or change). Therefore, we also estimated the
proportion of women who presented with a NICE guide-
line symptom that was new in the previous 12 months.
The time period covered by downloading the last 10
consultation entries varied between women (median
6.0 months inter-quartile range 2.8-11.5). To use all
available data for each woman we used the Kaplan-Meier
method to estimate the proportion of women with a NICE
guideline symptom in the reference week who had pre-
sented previously with that symptom as a function of
time. From this we estimated the proportion who had at
least one NICE guideline symptom for which they had not
presented in the previous year (ie ‘new’). We multiplied
this by the proportion of registered women aged 45–74
who presented with a NICE symptom to calculate the
proportion (p) who would present during the week with
a NICE guideline symptom that was new in the last year.
The Delta method was used to calculate the variance to
obtain confidence intervals for our estimate of NICE
guideline symptoms new in the last year (taking into ac-
count the Kaplan-Meier estimate).
We calculated the proportion of women aged 45–74
who presented during the reference week with symptoms
with 95% confidence intervals (for proportions) for
women with:
 Any ovarian cancer symptom
 Any NICE guideline symptom
 Any Index 2 symptom
 Any ‘new’ NICE guideline symptom
 At least two Index 2 symptoms
We approximate the proportion of all women aged
45–74 that would be offered testing over one year accord-
ing to different symptom categories using the equation:
1− 1−pð Þ52
where p is the proportion of women to be offered
testing in a single week. Confidence intervals (95%) were
calculated using the same equation and were based on
the binomial distribution.
Results
A total of seven practices were approached of which five
agreed to participate. Of these, one was excluded because
the list size was too small (below 5500).
The combined list size was 38,921, of whom 5737 were
women aged 45–74. Table 1 shows GP practice details
and the number of women aged 45–74 who consulted
during the reference week for each practice and overall.
Although the proportion of registered females in the
target age range at each practice was broadly comparable
between practices (11%-17%), the proportion that con-
sulted during the week varied considerably (e.g. almost 3
times as many women presented at Chrisp Street (14%)
than at Boundary House and Woosehill practice (both
5%)). Of the women who consulted during the week the
proportion who reported any symptom was similar across
practices. However, again there was almost a 3-fold differ-
ence between practices in the proportion of all women
aged 45–74 who presented with an ovarian cancer symp-
tom during the week (0.8% (Woosehill) cf. 2.2% (Chrisp
Street).
Table 2 shows the estimated proportion of women
who presented at each practice that would be offered
testing in one week based on different criteria. Accord-
ing to the basic testing scenario of any ovarian cancer
symptom, 16.8% of women aged 45–74 who present
over one week would be ‘screened’ (equivalent to 1.4% of
all women in the age group each week). It is much less
common to have two or more Index 2 symptoms: 0.8%
of women who present over one week had at least two
Index 2 symptoms.
Our estimates for the proportion of women aged 45–74
presenting over one year are shown in Table 3. According
to the survival analysis 45.0% of women with a NICE
guideline symptom in the reference week would not have
had that same symptom within the previous 12 months
(i.e. for 45.0% of those with a NICE symptom, at least
one NICE symptom was new). Extrapolation yielded
11.9% (95% CI 5.0%, 18.3%) of all women aged 45–74
would present with a new NICE guideline symptom over
one year. However, it should be noted that the estimates
obtained from individual practices varied considerably.
Discussion
Summary
According to our estimates, about a quarter of women
aged 45–74 presenting to GP primary care would be
offered symptoms-based screening for a NICE guideline
symptom each year, however, this reduced to about a fifth
when only ‘new’ symptoms were considered.
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Despite having diverse locations, the four GP practices
studied showed comparable proportions of women aged
45–74 who presented during the reference week. By con-
trast, the proportion of women in the target age range
who presented with at least one ovarian cancer symptom
relative to list size differed widely across surgeries.
Strengths and limitations
A key strength of the study is that we collected data
from a mixture of urban and non-urban practices to
obtain a representative sample. In addition, having the
last 10 consultations entries before the date of download
provided information on symptom development. We
used several testing scenarios to estimate the proportion
of women who would be offered symptoms-based ovarian
cancer screening, including an assessment of whether
symptoms were new in the last year (testing is unlikely to
be offered for longstanding symptoms). We used an age
range that is most likely to be chosen for symptoms-based
ovarian cancer screening; ovarian cancer incidence is
much higher in postmenopausal women aged ≥45 and
screening is not usually offered to those aged over 74.
Finally, data were collected before initiatives to raise
symptom awareness and encourage early presentation
were commonplace (e.g. National Awareness and Early
Diagnosis Initiative - NAEDI).
The main limitations are that the study was small and
only records from women consulting during a single
week were examined. This period is too short to take
seasonal variations in consultations (e.g. flu season) into
account. Additionally, we only studied four GP practices
and these were seen to be heterogeneous. Another draw-
back is our inability to accurately assess other factors
which would inform the decision to offer screening to
Table 1 Details of GP practices and women aged 45–74 who presented during the reference week
Chrisp St Woosehill Northcroft Boundary TOTAL
List size 11504 10652 8928 7837 38921
Total number females 5645 (49%) 5388 (51%) 4503 (50%) 4022 (51%) 19558 (50%)
Women aged 45-74 1210 (11%) 1809 (17%) 1457 (16%) 1261 (16%) 5737 (15%)
GPs at practice
Full-time 1 3 3 3 10
Part-time 11 2 2 1 16
Total 12 5 5 4 26
Women aged 45–74 who presented during the week
with GP 133 56 124 38 351
with Nurse 50 36 45 24 155
Total (GP or nurse) 168* (14%) 85 (5%) 163† (11%) 59 (5%) 475‡ (8%)
Proportion of presenting women who had ≥1 symptom
during the week
112/168 (66.7%) 50/85 (58.8%) 93/163 (57.1%) 38/59 (64.4%) 293/475 (61.7%)
Proportion of all women aged 45–74 who presented
with ≥1 ovarian cancer symptom during the week
27/1210 (2.2%) 14/1809 (0.8%) 28/1457 (1.9%) 11/1261 (0.9%) 80/5737 (1.4%)
*Excludes one woman with ovarian cancer.
†Excludes one woman with ovarian cancer and two women receiving treatment for other cancers.
‡Excludes two women with ovarian cancer and two women receiving treatment for other cancers.
Table 2 Estimated proportion of women presenting during the week who would be offered symptoms-based ‘screening’
according to different testing thresholds
Chrisp Street Woosehill Northcroft Boundary TOTAL
(n =168) (n =85) (n =163) (n =59) (n =475)
n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI
Any OC symptom 27 (16.1%) 10.9, 22.5 14 (16.5%) 9.3, 26.1 28 (17.2%) 11.7, 23.9 11 (18.6%) 9.7, 30.9 80 (16.8%) 13.6, 20.5
Any NICE symptom* 13 (7.7%) 4.2, 12.9 4 (4.7%) 1.3, 11.6 11 (6.7%) 3.4, 11.8 3 (5.1%) 1.1, 14.1 31 (6.5%) 4.5, 9.1
Any Index 2 symptom† 11 (6.6%) 3.3, 11.4 3 (3.5%) 0.7, 10.0 8 (4.9%) 2.1, 9.4 3 (5.1%) 1.1, 14.1 25 (5.3%) 3.4, 7.7
≥2 Index 2 symptoms 2 (1.2%) 0.1, 4.2 0 (0%) 0.0, 4.2 2 (1.2%) 0.1, 4.4 0 (0%) 0.0, 6.1 4 (0.8%) 0.2, 2.1
OC = ovarian cancer, NICE = National Institute for Health and Clinical Excellence.
*Any one of persistent abdominal distension, feeling full (early satiety) and/or loss of appetite, pelvic or abdominal pain or increased urinary urgency
and/or frequency.
†Any one of pelvic abdominal pain or discomfort, loss of appetite, increase in abdominal size, able to feel a lump in the abdomen, or vaginal discharge.
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women, such as symptom frequency, severity and persist-
ence. In particular this could have led to overestimates of
the proportion that would be offered symptoms-based
screening.
Comparison with existing literature
Estimates from a recent UK study [18] were smaller than
ours. The authors used logistic regression to derive three
different weighted ovarian cancer scores were derived
using GP medical record data from 212 women with
ovarian cancer and 1060 age-matched controls. Seven
symptoms were included in each of the scores: bloating,
urinary frequency, rectal bleeding, postmenopausal bleeding,
loss of appetite, abdominal pain and abdominal distension.
The main score had a specificity of 91.3% which is equiva-
lent to 8.7% of women without ovarian cancer testing
positive on the score over one year.
A prospective study randomised GP practices to being
able to refer (or not refer) women aged ≥45 with any
one of a list of 19 symptoms potentially related to ovar-
ian cancer for immediate CA125 testing and transvaginal
ultrasound [19]. Compliance was poor and only 39 out
of 79 practices made referrals during the study period.
Referral patterns were also extremely variable between
GPs. Over the recruitment period that spanned almost
2½ years, only 317 women were referred.
Implications for research/practice
Based on our findings, symptoms-based screening would
result in roughly the same amount of screening as two
yearly population screening for any ovarian cancer symp-
tom, four yearly population screening for any NICE
guideline symptom and eight yearly population screening
for any ‘new’ NICE guideline symptom. One drawback of
symptoms-based screening is that it is necessary to wait
for symptoms to develop and for women to present.
Lower socioeconomic status is associated with delayed
presentation for some cancers [20], therefore, symptoms-
based screening could lead to an increase in the social
inequalities that already exist in ovarian cancer [21].
Nevertheless, current referral criteria for rapid access
gynaecological-oncology clinics (relevant to ovarian cancer)
only include two symptoms: suspicious pelvic mass and
postmenopausal bleeding (if not on hormone replacement
therapy). Symptoms-based screening could be a useful tool
when other typical ovarian cancer symptoms are present
but the index of suspicion is not sufficient to prompt
referral or more expensive investigations. This could
be particularly appealing given that the effectiveness of
population-based ovarian cancer screening remains
unclear. UKCTOCS (United Kingdom Collaborative Trial
of Ovarian Cancer Screening) is the largest randomised
trial of ovarian screening to date. Around 200,000 women
from the general population were randomised to either
screening with transvaginal ultrasound (TVS) or multimodal
screening with CA125 and TVS or no screening. Data from
the prevalent screening round found that sensitivity for
primary invasive epithelial ovarian/tubal cancer was 89.5%
and specificity was 99.8% in the multimodal arm [22]. Al-
though these data are encouraging, the final picture will need
to be balanced against unnecessary surgeries, complications
and most importantly, needs to be able to demonstrate a
mortality benefit. Mortality data are due in 2015 and are
expected to provide major insights into ovarian screening.
Although our estimates for women who would require
symptoms-based testing are relatively large, the extrapo-
lations over one year are somewhat crude. Furthermore,
any testing threshold for symptoms-based screening is
likely to include a criterion for symptom persistence
which was unaccounted for in this analysis. The NICE
guidelines [14] and the symptom index produced by
Goff et al. [23] stipulate that symptoms should occur
more than 12 times per month Applying similar criteria
should further reduce the number of women who require
testing, as would the use of a score or similar. In this
study, only 3.6% (95% CI 1.0%-8.9%) of women aged 45–74
would have had testing in one year if the requirement was
for two or more Index 2 symptoms. Additionally, testing
would not be offered to women who have already been
recently tested (say the last 6–12 months) which would
also reduce testing numbers.
Conclusions
Over one year, between 11.9%-51.8% of women aged
45–74 who present to primary care would be offered
symptoms-based ovarian screening depending on the
Table 3 Extrapolated estimates of the proportion of women
aged 45–74 who would be offered symptoms-based
‘screening’ over 1 year according to different testing
thresholds
Percentage 95% CI
Any ovarian cancer symptom 51.8% 44.0%-59.7%
Any NICE guideline symptom* 24.6% 17.4%-33.0%
Any new (in last year) NICE
guideline symptom*†
11.9% 5.0%-18.3%
Any Index 2 symptom‡ 20.3% 13.7%-28.5%
≥2 Index 2 symptoms‡ 3.6% 1.0%-8.9%
NICE = National Institute for Health and Clinical Excellence,
CI = confidence interval.
*Any one of persistent abdominal distension, feeling full (early satiety) and/or
loss of appetite, pelvic or abdominal pain or increased urinary urgency
and/or frequency.
†Estimated using Kaplan Meier.
‡Any one of pelvic abdominal pain or discomfort, loss of appetite, increase in
abdominal size, able to feel a lump in the abdomen, or vaginal discharge.
Note: Extrapolations did not account for variation between practices in the
proportion of women aged 45–74 with ≥1 ovarian cancer symptom. The
estimated proportion of women presenting with an ovarian cancer symptom
over one year varied from 32.2% (Woosehill Practice) to 69.1% (Chrisp
Street Practice).
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guidelines adopted. Although there are other issues to
consider, these data are encouraging since the numbers
are considerably less than those required for annual (or
even biennial) population screening and in reality, stricter
criteria would be applied which would further reduce
these figures.
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